Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease.

9 Aug 2010

Scientists identify role of PNPASE in regulating RNA import into mitochondria

Researchers at UCLA's Jonsson Comprehensive Cancer Center and the departments of Chemistry and Biochemistry and Pathology and Laboratory Medicine have uncovered a role for an essential cell protein in shuttling RNA into the mitochondria, the energy-producing "power plant" of the cell. The import of nucleus-encoded small RNAs into mitochondria is essential for the replication, transcription and translation of the mitochondrial genome, but the mechanisms that deliver RNA into mitochondria remain poorly understood.

7 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

Research examines effects of orthostatic hypotension in adults, children

A simple variation to the tried and true method of checking blood pressure can reveal startling information about both older and younger persons, new research suggests.

4 Aug 2010

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Impax Laboratories, Inc. today reported strong growth in the second quarter of 2010 due to an increase in sales from its Global Product sales channel. Total revenue increased $94.7 million to $153.1 million driven by continued strong sales of generic Adderall XR and generic Flomax for which there were no amounts in the second quarter of 2009, as well as increased sales of the Company's fenofibrate products.

3 Aug 2010

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth.

3 Aug 2010

Placebo response in Parkinson's disease treatment varies with patient expectations

Individuals with Parkinson's disease were more likely to have a neurochemical response to a placebo medication if they were told they had higher odds of receiving an active drug, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Aug 2010

GG genotype may increase severity of multiple sclerosis symptoms: Study

A new study shows a gene variant may increase the severity of multiple sclerosis (MS) symptoms. The research will be published in the August 3, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.For the study, researchers screened the oligoadenylate synthetase gene in 401 people with MS, 394 people without MS and 178 people receiving the MS treatment beta interferon.

3 Aug 2010

Today's OpEds: Medicaid and the safety net; Health reform law's impact on long-term care and health costs

Late last week, the federal government provided a road map [for how to help those with little access to care] by extending an existing agreement that allows up to $25 million in Medicaid payments to hospitals to be diverted instead to clinics that serve the uninsured. You might think that would be a hard sell for hospitals; after all, they're experiencing sharp growth in the number of uninsured patients they serve. But St. Louis-area hospitals willingly have been sharing those payments with clinics for a decade. Without them, there simply wouldn't be a health care safety net to meet the region's needs (8/1).

2 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Partners in ENIAC project announce details of multinational/multidisciplinary program

The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.

30 Jul 2010

Researchers find new pathway that leads to brain cell death in neurodegenerative disorders

Although their genetic underpinnings differ, Alzheimer's disease, Parkinson's disease and Huntington's disease are all characterized by the untimely death of brain cells. What triggers cell death in the brain? According to a new study published by researchers at Sanford-Burnham Medical Research Institute in the July 30 issue of Molecular Cell, the answer in some cases is the untimely transfer of a gaseous molecule (known as nitric oxide, or NO) from one protein to another.

30 Jul 2010

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.

30 Jul 2010

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP).

30 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

Scientists identify new targets to develop treatment for HD

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development.

29 Jul 2010

REM sleep behavior disorder may later lead to neurologic disorders

A new study shows that a sleep disorder may be a sign of dementia or Parkinson's disease up to 50 years before the disorders are diagnosed. The research is published in the July 28, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

29 Jul 2010

Loss of key nerve cells cause Parkinson's disease: Research

Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.

29 Jul 2010

Scientists study mutant protein lump formation process to control brain cell death

Australian scientists have identified the behaviour of the mutant protein 'huntingtin' which leads to the fatal Huntington's disease providing potential targets to treat the disease, a University of Melbourne study reveals.

29 Jul 2010

Research on method to open blood-brain barrier for safe cancer drug delivery

One of the human body's most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof security system, however, limits the ability of physicians to deliver drugs directly to the brain, making it difficult to treat brain tumors. Researchers at Rensselaer Polytechnic Institute are endeavoring to solve this problem by investigating new methods for bypassing the blood-brain barrier and combating the spread of brain cancer.

28 Jul 2010

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Scientists identify role of PNPASE in regulating RNA import into mitochondria

TEMPO study recommends early administration of Azilect in PD patients

Research examines effects of orthostatic hypotension in adults, children

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Placebo response in Parkinson's disease treatment varies with patient expectations

GG genotype may increase severity of multiple sclerosis symptoms: Study

Today's OpEds: Medicaid and the safety net; Health reform law's impact on long-term care and health costs

Xeomin receives FDA approval for treatment of cervical dystonia

Partners in ENIAC project announce details of multinational/multidisciplinary program

Researchers find new pathway that leads to brain cell death in neurodegenerative disorders

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Scientists identify new targets to develop treatment for HD

REM sleep behavior disorder may later lead to neurologic disorders

Loss of key nerve cells cause Parkinson's disease: Research

Scientists study mutant protein lump formation process to control brain cell death

Research on method to open blood-brain barrier for safe cancer drug delivery

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in